<DOC>
	<DOCNO>NCT00973245</DOCNO>
	<brief_summary>This exploratory investigation safety , pharmacokinetic ( PK ) pharmacodynamic ( PD ) effect BAY59-7939 multiple oral dos 10 mg , 15 mg 20 mg daily ( od ) Japanese subject non-valvular atrial fibrillation ( originally describe Japanese ) .</brief_summary>
	<brief_title>BAY59-7939 Atrial Fibrillation Once Daily ( OD )</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Japanese subject nonvalvular AF meet follow criterion : Male subject age 20 year old postmenopausal female subject Subjects persistent paroxysmal nonvalvular AF &gt; /=2 episodes enrollment , least 1 verified ECG recording within 4 week randomization Subjects risk stroke follow : Subjects least one risk factor thromboembolism ( hypertension , diabetes mellitus , coronary artery disease , congestive heart failure ) . Subjects age 60 year old regardless existence risk factor . History presence stroke transient ischemic attack . History intracerebral hemorrhage . History presence bleed randomization ; intraocular gastrointestinal bleeding within last 6 month prior randomization .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>BAY59-7939</keyword>
	<keyword>Rivaroxaban</keyword>
	<keyword>Non-valvular atrial fibrillation</keyword>
	<keyword>Japanese Patients</keyword>
	<keyword>Phase II</keyword>
</DOC>